Protein expression profiling of cytokines and cytokine receptors on purified chronic lymphocytic leukemia cells from patients with favourable prognostic indicators

References

• Carney D A, Wierda W G. Genetics and molecular biology of chronic lymphocytic leukemia. Curr Treat Options Oncol 2005; 6: 215–225
   PubMedGoogle Scholar
• Rai K R. Pathophysiologic mechanisms of chronic lymphocytic leukemia and their application to therapy. Exp Hematol 2007; 35: 134–136
   PubMed Web of Science ®Google Scholar
• Ghia P, Circosta P, Scielzo C, Vallario A, Camporeale A, Granziero L, Caligaris-Cappio F. Differential effects on CLL cell survival exerted by different microenvironmental elements. Curr Top Microbiol Immunol 2005; 294: 135–145
   PubMed Web of Science ®Google Scholar
• Munk Pedersen I, Reed J. Microenvironmental interactions and survival of CLL B-cells. Leuk Lymphoma 2004; 45: 2365–2372
   PubMed Web of Science ®Google Scholar
• Shanafelt T D, Kay N E. The clinical and biologic importance of neovascularization and angiogenic signaling pathways in chronic lymphocytic leukemia. Semin Oncol 2006; 33: 174–185
   PubMed Web of Science ®Google Scholar
• Kay N E, Shanafelt T D, Strege A K, Lee Y K, Bone N D, Raza A. Bone biopsy derived marrow stromal elements rescue chronic lymphocytic leukemia B-cells from spontaneous and drug induced cell death and facilitates an “angiogenic switch.”. Leuk Res 2007; 31: 899–906
   PubMed Web of Science ®Google Scholar
• Buschle M, Campana D, Carding S R, Richard C, Hoffbrand A V, Brenner M K. Interferon γ inhibits apoptotic cell death in B cell chronic lymphocytic leukemia. J Exp Med 1993; 177: 213–218
   PubMed Web of Science ®Google Scholar
• Cordingley F T, Bianchi A, Hoffbrand A V, Reittie J E, Heslop H E, Vyakarnam A, et al. Tumour necrosis factor as an autocrine tumour growth factor for chronic B-cell malignancies. Lancet 1988; 1: 969–971
   PubMed Web of Science ®Google Scholar
• Dancescu M, Rubio-Trujillo M, Biron G, Bron D, Delespesse G, Sarfati M. Interleukin 4 protects chronic lymphocytic leukemic B cells from death by apoptosis and upregulates Bcl-2 expression. J Exp Med 1992; 176: 1319–1326
   PubMed Web of Science ®Google Scholar
• Larsson L G, Carlsson M, Schena M, Lantz M, Caligaris-Cappio F, Nilsson K. Interleukin-2 enhances the production of tumor necrosis factor-α in activated B-type chronic lymphocytic leukemia (B-CLL) cells. Leukemia 1993; 7: 226–234
   PubMed Web of Science ®Google Scholar
• Aderka D, Maor Y, Novick D, Engelmann H, Kahn Y, Levo Y, et al. Interleukin-6 inhibits the proliferation of B-chronic lymphocytic leukemia cells that is induced by tumor necrosis factor-α or -β. Blood 1993; 81: 2076–2084
   PubMed Web of Science ®Google Scholar
• Tangye S G, Weston K M, Raison R L. Interleukin-10 inhibits the in vitro proliferation of human activated leukemic CD5+ B-cells. Leuk Lymphoma 1998; 31: 121–130
   PubMed Web of Science ®Google Scholar
• Barcellini W, Montesano R, Clerici G, Zaninoni A, Imperiali F G, Calori R, et al. In vitro production of anti-RBC antibodies and cytokines in chronic lymphocytic leukemia. Am J Hematol 2002; 71: 177–183
   PubMed Web of Science ®Google Scholar
• Mainou-Fowler T, Proctor S J, Miller S, Dickinson A M. Expression and production of interleukin 4 in B-cell chronic lymphocytic leukaemia. Leuk Lymphoma 2001; 42: 689–698
   PubMed Web of Science ®Google Scholar
• Jansen J H, Wientjens G J, Willemze R, Kluin-Nelemans J C. Production of tumor necrosis factor-α by normal and malignant B lymphocytes in response to interferon-α, interferon-γ and interleukin-4. Leukemia 1992; 6: 116–119
   PubMed Web of Science ®Google Scholar
• Foa R, Massaia M, Cardona S, Tos A G, Bianchi A, Attisano C, et al. Production of tumor necrosis factor-α by B-cell chronic lymphocytic leukemia cells: a possible regulatory role of TNF in the progression of the disease. Blood 1990; 76: 393–400
   PubMed Web of Science ®Google Scholar
• Wognum A W, Lansdorp P M, Humphries R K, Krystal G. Detection and isolation of the erythropoietin receptor using biotinylated erythropoietin. Blood 1990; 76: 697–705
   PubMed Web of Science ®Google Scholar
• Damle R N, Wasil T, Fais F, Ghiotto F, Valetto A, Allen S L, et al. Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood 1999; 94: 1840–1847
   PubMed Web of Science ®Google Scholar
• Admirand J H, Rassidakis G Z, Abruzzo L V, Valbuena J R, Jones D, Medeiros L J. Immunohistochemical detection of ZAP-70 in 341 cases of non-Hodgkin and Hodgkin lymphoma. Mod Pathol 2004; 17: 954–961
   PubMed Web of Science ®Google Scholar
• McCarthy H, Wierda W G, Barron L L, Cromwell C C, Wang J, Coombes K R, et al. High expression of activation-induced cytidine deaminase (AID) and splice variants is a distinctive feature of poor-prognosis chronic lymphocytic leukemia. Blood 2003; 101: 4903–4908
   PubMed Web of Science ®Google Scholar
• Chiorazzi N, Ferrarini M. Evolving view of the in-vivo kinetics of chronic lymphocytic leukemia B cells. Hematology (Am Soc Hematol Educ Program) 2006; 273–278, 512
   PubMedGoogle Scholar
• Levesque M C, O'Loughlin C W, Weinberg J B. Use of serum-free media to minimize apoptosis of chronic lymphocytic leukemia cells during in vitro culture. Leukemia 2001; 15: 1305–1307
   PubMed Web of Science ®Google Scholar
• Zent C S, Chen J B, Kurten R C, Kaushal G P, Marie Lacy H, Schichman S A. Alemtuzumab (CAMPATH 1H) does not kill chronic lymphocytic leukemia cells in serum free medium. Leuk Res 2004; 28: 495–507
   PubMed Web of Science ®Google Scholar
• Liu B C, Zhang L, Lv L L, Wang Y L, Liu D G, Zhang X L. Application of antibody array technology in the analysis of urinary cytokine profiles in patients with chronic kidney disease. Am J Nephrol 2006; 26: 483–490
   PubMed Web of Science ®Google Scholar
• Jinquan T, Jacobi H H, Jing C, Millner A, Sten E, Hviid L, et al. CCR3 expression induced by IL-2 and IL-4 functioning as a death receptor for B cells. J Immunol 2003; 171: 1722–1731
   PubMed Web of Science ®Google Scholar
• Kishimoto T. The biology of interleukin-6. Blood 1989; 74: 1–10
   PubMed Web of Science ®Google Scholar
• Van Snick J. Interleukin-6: an overview. Annu Rev Immunol 1990; 8: 253–278
   PubMed Web of Science ®Google Scholar
• Fayad L, Keating M J, Reuben J M, O'Brien S, Lee B N, Lerner S, Kurzrock R. Interleukin-6 and interleukin-10 levels in chronic lymphocytic leukemia: correlation with phenotypic characteristics and outcome. Blood 2001; 97: 256–263
   PubMed Web of Science ®Google Scholar
• Biondi A, Rossi V, Bassan R, Barbui T, Bettoni S, Sironi M, et al. Constitutive expression of the interleukin-6 gene in chronic lymphocytic leukemia. Blood 1989; 73: 1279–1284
   PubMed Web of Science ®Google Scholar
• Lahat N, Aghai E, Maroun B, Kinarty A, Quitt M, Froom P. Increased spontaneous secretion of IL-6 from B cells of patients with B chronic lymphatic leukaemia (B-CLL) and autoimmunity. Clin Exp Immunol 1991; 85: 302–306
   PubMed Web of Science ®Google Scholar
• Hulkkonen J, Vilpo J, Vilpo L, Hurme M. Diminished production of interleukin-6 in chronic lymphocytic leukaemia (B-CLL) cells from patients at advanced stages of disease. Tampere CLL Group. Br J Haematol 1998; 100: 478–483
   PubMed Web of Science ®Google Scholar
• Emilie D, Leger-Ravet M B, Devergne O, Raphael M, Peuchmaur M, Coumbaras J, et al. Intratumoral production of IL-6 in B cell chronic lymphocytic leukemia and B lymphomas. Leuk Lymphoma 1993; 11: 411–417
   PubMed Web of Science ®Google Scholar